News and Announcements
PharmAust Ltd – Human Cancer Trial Advancing to Second Patient
- Published October 23, 2014 12:56PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX Release – Tuesday 21 October 2014
PharmAust Limited (ASX; PAA & PAAO) is pleased to report that it is now advancing to the treatment of the second patient in its “First in Man” trial with PPL-1. Following the approval of the study by the Royal Adelaide Hospital research Ethics Committee in April 2014, the Company commenced recruitment and treatment of the first patient with its anti-cancer drug PPL-1. Unfortunately, the first patient passed away due to reasons unrelated to the study drug and this has understandably resulted in a standard process of investigations resulting in delays in the treatment of the second patient.
CMAX with the assistance and guidance of the Principal Investigator, Professor Michael Brown, will resubmit the ethics application to the Royal Adelaide Hospital Ethic Committee to seek approval for advancing the clinical trial.
To view the full ASX Release please, click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
